(4S,5S,6S)-4-allyl-6-ethyl-4-hydroxy-5-methyltetrahydro-2H-pyran-2-one | 1439376-58-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: (4S,5S,6S)-4-allyl-6-ethyl-4-hydroxy-5-methyltetrahydro-2H-pyran-2-one
• 英文别名: (4S,5S,6S)-6-ethyl-4-hydroxy-5-methyl-4-prop-2-enyloxan-2-one
• CAS: 1439376-58-5
• 化学式: C₁₁H₁₈O₃
• 分子量: 198.262
• InChiKey: YYVJFRRZNGPJSM-QXEWZRGKSA-N

物化性质

• 熔点：
  56-58 °C
• 沸点：
  309.5±30.0 °C(predicted)
• 密度：
  1.010±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4S,5S,6S)-4-allyl-6-ethyl-4-hydroxy-5-methyltetrahydro-2H-pyran-2-one 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 四(三苯基膦)钯 、 四丁基氟化铵 、 thallium (I) ethoxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 19.17h， 生成 (5E,7R,8S,9R,10R,13Z,15S,16S)-16-((2E,4E)-6-((2S,3S,4S)-2-ethyl-4-hydroxy-3-methyl-6-oxotetrahydro-2H-pyran-4-yl)hexa-2,4-dien-2-yl)-10-hydroxy-8-(methoxymethoxy)-6,7,9,15-tetramethyloxacyclohexadeca-5,13-dien-11-yn-2-one
  参考文献：
  名称：

  不同的全合成抗有丝分裂剂Leodermatolide。

  摘要：

  微妙但与众不同：生物学上很有前途的抗有丝分裂剂leiodermatolide的立体结构尚不确定。以开环炔烃复分解为关键步骤的短而有效且灵活的全合成方法现已解决了这个难题。所示结构和可能的异构体在1 H NMR光谱中的细微差异证明对于该赋值是无价的。

  DOI：

  10.1002/anie.201206670
• 作为产物：
  描述：

  (2R)-2-(苯甲酰基氧基)-3-戊酮 在 2,6-二甲基吡啶 、 盐酸 、 三氟化硼乙醚 、 氯代二环己基硼烷 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 水 为溶剂， 反应 3.08h， 生成 (4S,5S,6S)-4-allyl-6-ethyl-4-hydroxy-5-methyltetrahydro-2H-pyran-2-one
  参考文献：
  名称：

  抗有丝分裂海洋大环内酯 (−)-Leiodermatolide 的全合成

  摘要：

  Leiodermatolide 是一种从海洋海绵 Leiodermatium sp 中分离出来的抗有丝分裂大环内酯。其潜在的新颖的微管蛋白靶向作用机制使其成为抗癌药物发现的令人兴奋的先导。为了追求可持续的供应，我们报告了基于钯介导的片段组装和大内酯化的收敛序列的高度立体控制的全合成（3.2%产率）。通过采用适当的乳酸酯衍生酮7的对映体，硼介导的羟醛反应用于配置三个关键片段2、5和6。

  DOI：

  10.1002/anie.201310164

文献信息

• Leiodermatolide derivatives and their use
  申请人：Studiengesellschaft Kohle mbH

  公开号：EP3012257A1

  公开（公告）日：2016-04-27

  The present invention refers to leiodermatolide derivatives and the use thereof as cytotoxic agents, in particular in the form of ADC s.

  本发明涉及雷欧皮质内酯衍生物及其作为细胞毒性药剂的用途，特别是作为ADC的形式。
• Total Synthesis of Leiodermatolide A via Transfer Hydrogenative Allylation, Crotylation, and Propargylation: Polyketide Construction beyond Discrete Allyl- or Allenylmetal Reagents
  作者：Yuk-Ming Siu、James Roane、Michael J. Krische

  DOI：10.1021/jacs.1c06062

  日期：2021.7.21

  The total synthesis of leiodermatolide A was accomplished in 13 steps (LLS). Transfer hydrogenative variants of three carbonyl additions that traditionally rely on premetalated reagents (allylation, crotylation, and propargylation) are deployed together in one total synthesis.

  leiodermatolide A 的全合成分 13 个步骤 (LLS) 完成。传统上依赖于预金属化试剂（烯丙基化、巴豆酰化和炔丙基化）的三种羰基加成的转移氢化变体在一个全合成中一起部署。
• Synthesis, Molecular Editing, and Biological Assessment of the Potent Cytotoxin Leiodermatolide
  作者：Damien Mailhol、Jens Willwacher、Nina Kausch-Busies、Elizabeth E. Rubitski、Zhanna Sobol、Maik Schuler、My-Hanh Lam、Sylvia Musto、Frank Loganzo、Andreas Maderna、Alois Fürstner

  DOI：10.1021/ja508846g

  日期：2014.11.5

  It was by way of total synthesis that the issues concerning the stereostructure of leiodermatolide (1) have recently been solved; with the target now being unambiguously defined, the mission of synthesis changes as to secure a meaningful supply of this exceedingly scarce natural product derived from a deep-sea sponge. To this end, a scalable route of 19 steps (longest linear sequence) has been developed, which features a catalytic asymmetric propargylation of a highly enolizable beta-keto-lactone, a ring closing alkyne metathesis and a modified Stille coupling as the key transformations. Deliberate digression from this robust blueprint brought a first set of analogues into reach, which allowed the lead qualities of 1 to be assessed. The acquired biodata show that 1 is a potent cytotoxin in human tumor cell proliferation assays, distinguished by GI(50) values in the =3 nM range even for cell lines expressing the Pgp efflux transporter. Studies with human U2OS cells revealed that 1 causes mitotic arrest, micronucleus induction, centrosome amplification and tubulin disruption, even though no evidence for direct tubulin binding has been found in cell-free assays; moreover, the compound does not seem to act through kinase inhibition. Indirect evidence points at centrosome declustering as a possible mechanism of action, which provides a potentially rewarding outlook in that centrosome declustering agents hold promise of being inherently selective for malignant over healthy human tissue.